Cargando…
Single‐Dose and Multiple‐Dose Pharmacokinetics of Vaniprevir in Healthy Men
Vaniprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease. The aim of these double‐blind, placebo‐controlled phase I studies was to evaluate the safety and pharmacokinetics of vaniprevir in healthy male volunteers. The primary objective for both studies was the safety and tolerabilit...
Autores principales: | Caro, L, de Hoon, J, Depré, M, Cilissen, C, Miller, J, Gao, W, Panebianco, D, Guo, Z, Troemel, SL, Anderson, MS, Uemura, N, Butterton, J, Wagner, J, Wright, DH |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402189/ https://www.ncbi.nlm.nih.gov/pubmed/28796416 http://dx.doi.org/10.1111/cts.12482 |
Ejemplares similares
-
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
por: Krishna, Rajesh, et al.
Publicado: (2016) -
No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole
por: Feng, H‐P, et al.
Publicado: (2017) -
Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
por: Rizk, Matthew L., et al.
Publicado: (2018) -
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
por: Rhee, Elizabeth G., et al.
Publicado: (2018) -
Single Oral Dose Pharmacokinetics of Decursin and Decursinol Angelate in Healthy Adult Men and Women
por: Zhang, Jinhui, et al.
Publicado: (2015)